title: Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma.
authors.forename: Ludivine
authors.initials: L
authors.lastname: Gressier
authors.forename: Philippe
authors.initials: P
authors.lastname: Guilpain
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gorin
authors.forename: Agnès
authors.initials: A
authors.lastname: Carlotti
authors.forename: Claire
authors.initials: C
authors.lastname: Goulvestre
authors.forename: Françoise
authors.initials: F
authors.lastname: Boitier
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
authors.forename: Marie-Françoise
authors.initials: MF
authors.lastname: Avril
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Nicolas
authors.initials: N
authors.lastname: Dupin
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D016736:Antiphospholipid Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D001706:Biopsy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D004359:Drug Therapy, Combination; D006225:Hand; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009336:Necrosis; D011092:Polyethylene Glycols / Q000009:adverse effects; D011994:Recombinant Proteins; D012867:Skin / Q000276:immunology* / Q000473:pathology; D014034:Toes; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b